CVS Health reported a 7.3% revenue increase in Q2 to $106.1 billion and raised its full-year revenue forecast to at least $414 billion, alongside improved earnings per share guidance. Despite UBS lowering its price target to $118, analysts like Jefferies maintain a buy rating with a $120 target, indicating 21-28% potential upside. The company is also focusing on reducing debt, supported by strong cash flow and a leverage ratio of about 3.5 times. This financial strength and analyst confidence suggest positive investment potential for CVS stock.
Nearly 1 million Medicare Advantage members face plan shutdowns from providers like UnitedHealth and Humana, risking loss of current coverage. While this reduces insurer costs and improves margins, affected members must act by December 7 to secure Me...
CVS Health has opened its first pharmacy-focused CVS Pharmacy in Roxbury, Boston, with plans to open nearly 20 such locations nationwide in 2026. These smaller, community-tailored pharmacies aim to improve access to prescription medications, immuniza...
Jim Cramer highlights three stocks with different outlooks: CVS Health is considered 'insanely cheap' at around $86 due to overblown concerns about its Caremark unit and strong overall performance. ON Semiconductor is gaining after resolving Synaptic...
In response to a measles outbreak and statewide emergency in New York, CVS Health is offering measles-mumps-rubella (MMR) vaccinations at over 530 CVS Pharmacy locations and MinuteClinic sites across the state. The MMR vaccine is crucial to prevent t...
CVS Health announced it will hold a conference call on November 4, 2026, to discuss its third quarter financial results. The event will be webcast live on the company's investor relations website and archived for one year. CVS Health operates around ...
